Himadri Nath, Ph.D.

Himadri is a virologist with expertise in host-virus interactions, innate immunity, and viral pathogenesis. He completed his PhD in 2023 at the CSIR-Indian Institute of Chemical Biology, Kolkata, India, where his research focused on clinical dengue viruses and uncovered important serological cross-reactivity between dengue virus and SARS-CoV-2. This finding had significant diagnostic implications and drew considerable attention, particularly in dengue-endemic regions with high seroprevalence.

In 2023, he began his postdoctoral research at the Lovelace Biomedical Research Institute in Albuquerque, NM, where he studied the regulation of antiviral pathways, with a particular emphasis on interferon-stimulated genes (ISGs) and alternative splicing during viral infection. During this period, he discovered a novel ISG15 isoform that inhibits influenza A virus polymerase activity. He also developed a replication-competent influenza reporter virus system using a split-GFP approach.

In December 2025, Himadri joined the laboratory of Prof. Luis Martinez-Sobrido at Texas Biomedical Research Institute, where he is currently working on vaccine candidates for high-consequence viruses.